Homburger advised Idorsia, as the Six-listed commercial-stage biopharmaceutical company entered into a senior secured term loan agreement of up to CHF 250 million with investment funds managed by Pharmakon Advisors. The first tranche of CHF 150 million
Homburger advised UBS, acting through its London branch, on its issuance of EUR 1.25 bn in aggregate principal amount of fixed rate/floating rate notes due 2032 under its Euro Note Programme. The Homburger team The Homburger
Hombuerger advised Six-listed Temenos (SIX: TEMN), a specialist in banking technology, on its acquisition of Additiv, a Swiss fintech company providing a platform to orchestrate financial services. The transaction is subject to customary closing conditions.
Homburger advised UBS, acting through its Stamford branch, on its offering of USD 1.5 bn in aggregate principal amount of 4.678% Fixed-to-Floating Rate Senior Notes due 2030 under its medium-term notes program. The Homburger team The Homburger team
Homburger advised Raiffeisen Schweiz Genossenschaft on the issuance of its inaugural CHF 200 million 1.44% digital bail-in bond due 2033, to be traded on the SIX Swiss Exchange.
Homburger advised Amazon.com on its inaugural Swiss franc bond offering, while Schellenberg Wittmer acted as Swiss legal counsel to the joint lead managers, in a six-tranche CHF issuance totalling CHF 2.82 billion. Deal details The
Eli Lilly agreed to acquire LimmaTech Biologics — a Swiss clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases — for up to USD 780 m in cash, inclusive of an upfront payment and additional potential
Homburger acted as counsel to Zürcher Kantonalbank on the issuance of EUR 500 million 3.080 per cent Fixed Rate Bonds due May 2029, with BNP Paribas, Commerzbank, UBS AG London Branch, and Zürcher Kantonalbank serving as
Homburger advised Novartis Finance on the issuance of EUR 600 m 3.100 per cent. fixed rate notes due January 13, 2032, EUR 600 m 3.500 per cent. fixed rate notes due May 13, 2035 and EUR 500 m 4.000 per cent. fixed rate notes due
908 Devices Inc. (NASDAQ: MASS) completed the acquisition of Swiss-based Nirlab SA for a combination of cash and stock, including earn-out consideration. In connection with the deal, Homburger advised the buyer, while Wenger Vieli represented the
